In addition, in severe COVID-19, the levels of circulating mitochondrial DNA, S100A8/A9, and high mobility group box 1 were also significantly increased and were correlated with inferior clinical outcomes (11, 26). This evidence concerns the gene S100A8 and COVID-19.